Firebrick Pharma Limited (AU:FRE)
ASX:FRE
Want to see AU:FRE full AI Analyst Report?
FRE Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.09
Previous CloseN/A
Volume87.61K
Average Volume (3M)91.61K
Market Cap
AU$15.66M
Enterprise ValueAU$11.72M
Total Cash (Recent Filing)AU$1.44M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.63
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding284,754,000
10 Day Avg. Volume136,612
30 Day Avg. Volume91,607
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.38
Price to Sales (P/S)44.43
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetZero reported debt and a 0 debt-to-equity ratio materially lower financial risk and provide flexibility to fund development or partnerships without immediate leverage. This structural balance sheet strength extends runway and supports negotiations with licensors or CROs over the medium term.
Positive Gross MarginA ~36% gross margin indicates the core product/service economics can cover variable costs. If revenue recurrence is restored, gross profit can help absorb fixed overhead and make a path to operating profitability more achievable, supporting sustainable unit economics over time.
Reduced Cash Burn TrendMeaningful reduction in cash burn across 2024–2025 demonstrates improving operational discipline and cost control. A sustained downward trend in outflows extends financial runway, lowering near-term financing urgency and increasing chances to reach key development or commercialization milestones.
Bears Say
Sharp Revenue DeclineA ~74% revenue collapse undermines commercial traction and reduces scale economies. This structural decline makes fixed costs more burdensome, weakens negotiating leverage with partners and suppliers, and implies rebuilding sustainable revenue will require major product, market or commercial changes.
Deep And Persistent LossesVery large operating losses and an extreme negative net margin point to structural unprofitability at current scale. Such persistent deficits erode equity, limit reinvestment capacity, and make it difficult to attract favorable financing or achieve self-sustaining growth without a material change in revenue or cost structure.
Consistent Negative Free Cash FlowPersistent negative free cash flow means the company cannot fund operations internally and will need external capital to continue. That increases dilution or financing risk, constrains strategic flexibility for trials or commercialization, and is a durable threat to continuity absent funding or break-even progress.
Firebrick Pharma Limited News
FRE FAQ
What was Firebrick Pharma Limited’s price range in the past 12 months?
Firebrick Pharma Limited lowest share price was AU$0.05 and its highest was AU$0.09 in the past 12 months.
What is Firebrick Pharma Limited’s market cap?
Firebrick Pharma Limited’s market cap is AU$15.66M.
When is Firebrick Pharma Limited’s upcoming earnings report date?
Firebrick Pharma Limited’s upcoming earnings report date is Aug 27, 2026 which is in 118 days.
How were Firebrick Pharma Limited’s earnings last quarter?
Firebrick Pharma Limited released its earnings results on Mar 04, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Firebrick Pharma Limited overvalued?
According to Wall Street analysts Firebrick Pharma Limited’s price is currently Overvalued.
Does Firebrick Pharma Limited pay dividends?
Firebrick Pharma Limited does not currently pay dividends.
What is Firebrick Pharma Limited’s EPS estimate?
Firebrick Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Firebrick Pharma Limited have?
Firebrick Pharma Limited has 284,754,000 shares outstanding.
What happened to Firebrick Pharma Limited’s price movement after its last earnings report?
Firebrick Pharma Limited reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.407%.
Which hedge fund is a major shareholder of Firebrick Pharma Limited?
Currently, no hedge funds are holding shares in AU:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Firebrick Pharma Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:FRE Sentiment 90%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.66%
12-Months-Change
Fundamentals
Return on Equity
-140.26%
Trailing 12-Months
Asset Growth
24.27%
Trailing 12-Months
Company Description
Firebrick Pharma Limited
Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Technical Analysis
Hexima Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Inoviq Ltd
―